ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
PO Box 28,
South Australia 5007
North Terrace House,
19 North Terrace,
Hackney, SA, 5069
1300 128 339
Closed over Christmas
(reopened 1 February 2017)
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Hypothalamic-pituitary disorders increased risk for Fibromyalgia-associated symptoms
Saturday 28 September 2013
Patients with hypothalamic-pituitary disorders appeared to be at increased risk for fibromyalgia-associated symptoms, according to recent study results.
Researchers in Germany sent a questionnaire for evaluating fibromyalgia-associated symptoms to 121 patients with hypothalamic-pituitary disorders (HPD; mean age, 55.4 years; 61 men) from an endocrine outpatient clinic. A control group of 115 patients (mean age, 56.9 years; 58 men) had cardiac diseases, including coronary heart disease, pulmonary hypertension, chronic heart failure, cardiac valve disease, cardiomyopathy, hypertensive cardiac disease and arrhythmias.
Patients with HPD had more frequent fibromyalgia-associated symptoms involving muscular discomfort compared with controls (53.7% vs. 35.7%;P=.003). Autonomic symptoms were more prevalent in the HPD cohort compared with controls, in particular, cold hands, P=.039; flatulence, P=.022; and tiredness, P=.017. Patients with HDP also reported swollen and painful finger joints more often than controls (P=.002).
When patients with hypothalamic-pituitary hormone excess syndromes were compared with patients with a pituitary pathology without hormonal excess, no differences were detected regarding fibromyalgia-associated symptoms. Treatment modality for pituitary disease also was not associated with the fibromyalgia-associated symptom prevalence.
“Rheumatologists should consider such endocrine disorders in patients evaluated for fibromyalgia syndrome (FMS),” the researchers concluded. “It remains to be clarified though whether fibromyalgia-like symptoms in the HPD group reflect pre-existing vulnerability to FMS, or rather represent central changes promoting the occurrence of FMS.”
Disclosure: The researchers report no relevant financial disclosures.
The above originally appeared here.
blog comments powered by Disqus